Associated Papers
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI et al.
Oncotarget, 2016
27791198 (PubMed )
Supplement: oncotarget-07-77163-s002.xlsx › Patient_3_early_met_1
HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma.
Xue F et al.
Journal of Translational Medicine, 2015
26653219 (PubMed )
Supplement: 12967_2015_743_MOESM1_ESM.xlsx › Table_S4
Select a paper to view details